1 |
H. Lepor, W.O. Williford, M.J. Barry, M.K. Brawer, C.M. Dixon, G. Gormley, C. Haakenson, M. Machi, P. Narayan and R.J. Padley, The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia, New Eng. J. Med., 335, 533-539 (1996)
DOI
ScienceOn
|
2 |
J J. McNeil, O.H. Drummer, K. Raymond, E.L. Conway and W.J. Louis, The influence of food on the oral bioavailability of terazosin, Br. J. Clin. Pharmacol., 32, 775-776 (1991)
|
3 |
R.C. Sonders, Pharmacokinetics of terazosin, Am. J. Med., 80 (Suppl. 5B), 20-24 (1986)
|
4 |
S.J. Kim, D.K. Lim, I.J. Oh, S.C. Shin, H.S. Park, J.D. Moon and Y.B. Lee, Bioequivalence of Terasin tablet to Hytrine tablet (terazosin 2 mg). J. Kor. Pharm. Sci., 29, 61-66 (1999)
|
5 |
Y.J. Lee, J.H. Choi, J.H., S.H. Song, C.H. Seo, D.S. Kim, I.S. Park, K.H. Choi, H.K. Na, S.J. Chung, M.H. Lee and C.K. Shim, Development of K-BEtest_, a computer program for the analysis of bioequivalence, J. Kor. Pharm. Sci., 28, 223-229 (1998)
|
6 |
J.L. Pool, E.G. Nelson, A.A. Taylor and J.R. Mitchell, Terazosin (Hytrin): cumulative experience of clinical trials in the USA for the treatment of mild to moderate essential hypertension, Br. J. Clin. Pract. Symp., 54, 9-14 (1987)
|
7 |
S. Titmarsh and J.P. Monk, Terazosin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension, Drugs, 33, 461-477 (1987)
DOI
ScienceOn
|
8 |
J.C. Somberg, R. Achari and A.R. Laddu, Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events, Am. Heart J., 122, 901-905 (1991)
DOI
ScienceOn
|
9 |
R. Achari and A. Laddu, Terazosin: A new alpha adreno- ceptor blocking drug, J. Clin. Pharmacol., 32, 520-523 (1992)
DOI
|
10 |
P.G. Fabricius, P. Weizert, U. Dunzendorfer, J.M. Hannaford and C. Maurath, Efficacy of once a day terazosin in benign prostatic hyperplasia: a randamised, double blind placebo controlled clinical trial, Prostate Suppl., 3, 85-93 (1990)
|
11 |
Y.G. Yee, P.C. Rubin and P. Meffin, Prazosin determination by high-pressure liquid chromatography using fluorescence detection, J. Chromatogr., 172, 313-318 (1979)
DOI
ScienceOn
|
12 |
H. Lepor, G. Knapp-Maloney and H. Sunshine, A dose titration study evauating terazosin, a selective, once-a-day -blocker for the treatment of symptomatic benign prostatic hyperplasia, J. Urol., 144, 1393-1398 (1990)
DOI
|
13 |
P. Jungers, D. Ganeval, N. Pertuiset and P. Chauveau, Influence of renal insufficiency on the pharmacokinetics and pharmaco- dynamics of terazosin, Am. J. Med., 80 (suppl. 5B), 94-99 (1986)
|
14 |
J.J. McNeil, O.H. Drummer, E.L. Conway, B.S. Workman and W.J. Louis, Effect of age on pharmacokinetics of and blood pressure responses to prazosin and terazosin, J. Cardiova- scular Pharmacol., 10, 168-175 (1987)
DOI
ScienceOn
|
15 |
S.E. Patterson, Rapid and sensitive analysis of terazosin in plasma, peritoneal dialysis solution, and urine using high-performance liquid chromatography with fluorescence detec- tion, J. Chromatogr., 311, 206-212 (1984)
DOI
ScienceOn
|
16 |
S.E. Patterson, Terazocin kinetics after oral and intravenous doses, Clin. Pharmacol. Ther., 38, 423-427 (1985)
DOI
ScienceOn
|
17 |
R.K. Bhamra, R.J. Flanagan and D.W. Holt, High performance liquid chromatographic measurement of prazosin and terazosin in biological fluids, J. Chromatogr., 380, 216-221 (1986)
DOI
ScienceOn
|
18 |
N. Aoyagi, Bioequivalence test for oral dosage forms in Japan. Proceedings of the 44th Convention of The Pharmaceutical Society of Korea, 1995, pp. 50
|
19 |
K. Taguchi, R.F. Schaefers and M.C. Michel, Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics, Br. J. Clin. Pharmacol., 45, 49-55 (1998)
DOI
ScienceOn
|
20 |
E.E. Samara, B. Hosmane, C. Locke, C. Eason, J. Cavanaugh and G.R. Granneman, Assessment of the pharmacokinetic-pharmacodynamic interaction between terazosin and finasteride, J. Clin. Pharmacol., 36, 1169-1178 (1996)
DOI
ScienceOn
|